The partnership between Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK) has achieved a landmark milestone, with their jointly developed mRNA cancer vaccine for melanoma successfully hitting the primary endpoint in a Phase 3 clinical trial. This marks the world's first clinically validated therapeutic mRNA cancer vaccine, firmly establishing both the viability and commercial potential of mRNA technology in oncology. The announcement triggered a historic surge in Moderna's stock price, which closed up an astonishing 176.97% on the day, propelling the entire global mRNA biopharmaceutical sector into a powerful upward trajectory.
This breakthrough has initiated a comprehensive reassessment of valuation frameworks within China's mRNA technology space. Domestic companies possessing core technological capabilities and first-mover advantages are now entering a critical window for value re-rating. For years, cancer vaccines have been regarded as one of the ultimate frontiers in oncology treatment. However, the sector remained largely confined to research and development, with persistent market skepticism surrounding mRNA's practical application in tumor therapy and its commercial prospects. This skepticism has historically suppressed valuations for both global and domestic players in the field.
The decisive success of Moderna's Phase 3 melanoma mRNA vaccine trial has shattered these industry-wide preconceptions. For the first time, robust Phase 3 data has demonstrated conclusively that the cancer vaccine pathway is genuinely viable. This represents not merely a corporate triumph but a pivotal industry milestone, clearing away the most significant market doubts regarding the mRNA oncology sector and unlocking a vast new growth arena measured in the trillions. Capital markets have fundamentally restructured their valuation logic for mRNA technology.
The overseas validation and market surge directly benefit leading domestic companies deeply invested in the mRNA space. According to preliminary statistics, more than ten Chinese companies have entered the mRNA drug development arena, including Everest Medicines (HKEX: 01952) and Akeso (HKEX: 09926). In response to the Moderna catalyst, Everest Medicines saw its pre-market shares climb nearly 15% on the 20th. The company has built an integrated "AI + mRNA" platform, establishing a complete industrial chain spanning antigen design, sequence optimization, delivery systems, and scaled production. Its pipeline includes EVM16, a personalized mRNA tumor therapeutic vaccine that has completed its first human clinical trial.
Beyond these, more than a dozen other domestic enterprises are focused on mRNA vaccine development, with comparable players including Stemirna Therapeutics, Walvax Biotechnology, and CanSino Biologics. Among them, AIM VACCINE (HKEX: 06660) stands out as one of China's earliest entrants into mRNA technology, possessing an independently innovated technology platform that has been validated through industrial-scale production. The company's mRNA respiratory syncytial virus (RSV) vaccine and mRNA shingles vaccine have both received clinical trial approvals in China and the United States. Furthermore, in its application materials for listing on the NEEQ (National Equities Exchange and Quotations), AIM VACCINE has also disclosed the development of an mRNA solid tumor vaccine, positioning its pipeline and technical strengths at the forefront of the domestic industry.
AIM VACCINE has spent years deepening its expertise in core mRNA foundational technologies while establishing a comprehensive mRNA vaccine quality management system and GMP-compliant commercial-scale manufacturing facilities. Vaccines produced on its mRNA platform have undergone clinical validation involving tens of thousands of subjects, confirming the platform's safety and efficacy. The company has now streamlined the entire mRNA vaccine lifecycle, from research and development to production, enabling rapid industrialization of mRNA vaccine candidates upon receiving clinical approvals and accelerating the path to commercialization.
Previously, domestic mRNA technology platform companies represented by AIM VACCINE had long suffered from undervaluation, as the sector had yet to receive global clinical validation. Their technological worth and pipeline potential remained largely unrecognized by the capital markets. However, Moderna's breakthrough now thoroughly validates the correctness and foresight of the early investments made by these domestic players, dramatically enhancing the sector's certainty.
With the industry's moment having arrived, technological barriers fully addressed, and combined with China's vast oncology treatment demand alongside policy tailwinds favoring domestic substitution in biopharmaceuticals, the domestic mRNA cancer vaccine sector is poised for a period of rapid growth. Going forward, companies equipped with mature technology platforms, well-defined cancer vaccine pipelines, and extensive industrialization experience will continue to benefit from the dual advantages of sector expansion and valuation recovery, driving both share price appreciation and corporate value enhancement. These enterprises are set to emerge as the new growth engine within the biopharmaceutical sector.
Comments